
MIT researchers have found that lung tumor cells can become resistant to KRAS inhibitors by undergoing a transformation from adenocarcinoma to squamous cell carcinoma.
Image Credit: MIT News; Getty Images
(CC BY-NC-ND 3.0)
Scientific Frontline: Extended "At a Glance" Summary: Mechanisms of KRAS Inhibitor Resistance in Lung Cancer
The Core Concept: Lung cancer cells can develop resistance to KRAS-inhibiting drugs either by amplifying the KRAS gene to reactivate its signaling or by transforming their cellular identity from adenocarcinoma to squamous cell carcinoma.
Key Distinction/Mechanism: Unlike typical resistance where a tumor mutates to block a drug or simply overpowers it with more of the targeted protein, the lineage transformation mechanism involves the tumor cells fundamentally changing their type. This adeno-to-squamous transition allows the cancer to shut off KRAS signaling entirely and rely on alternative, currently unidentified pathways for continued growth.
Major Frameworks/Components:
- KRAS-G12C Mutation: A specific gene mutation driving uncontrolled cell growth, targeted by two FDA-approved inhibitors.
- Adeno-to-Squamous Transition: The tissue transformation process where lung adenocarcinomas (originating from surfactant-producing cells) transition into squamous cell carcinomas (originating from central airway cells).
- Nkx2-1: A transcription factor whose loss facilitates the transition from adenocarcinoma to squamous cell carcinoma.
- DeltaNp63 and SOX2: Transcription factors that, when overactive, stimulate the transformation to the squamous state.
- MAP Kinase Pathway: A cellular signaling pathway typically triggered by KRAS that stimulates cell growth.
.png)



_result.png)





.jpg)

.png)





